Fig. 1From: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in SpainDecision tree model of palivizumab versus non-prophylaxis in the prevention of RSV infection in preterm infantsBack to article page